AZD4547

For research use only. Not for use in humans.

目录号：S2801 别名： ABSK 091

CAS No. 1035270-39-3

AZD4547 (ABSK 091)是一种新型选择性的FGFR抑制剂，靶向作用于FGFR1/2/3，在无细胞试验中IC50为0.2 nM/2.5 nM/1.8 nM，对FGFR4， VEGFR2(KDR)具有微弱的作用活性，对IGFR， CDK2和p38几乎没有作用活性。Phase 2/3。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1801.43	现货
5mg	RMB 901.31	现货
10mg	RMB 1395.39	现货
50mg	RMB 4661.52	现货
100mg	RMB 7125.05	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的AZD4547发表文献80篇：

Cancer Cell, 2019, 35(3):504-518

PubMed: 30827889 ( click the link to review the publication )

Nature, 2018, 553(7686):101-105

PubMed: 29258295 ( click the link to review the publication )

Science, 2017, 10.1126/science.aan4368

PubMed: 29191878 ( click the link to review the publication )

Nature, 2016, 30;534(7609):647-51.

PubMed: 27338794 ( click the link to review the publication )

Sci Adv, 2021, 7(7)eabd2645

PubMed: 33579708 ( click the link to review the publication )

Cancer Res, 2021, canres.2276.2020

PubMed: 33685992 ( click the link to review the publication )

FASEB J, 2021, 35(2):e21286

PubMed: 33484478 ( click the link to review the publication )

Int J Oncol, 2021, 10.3892/ijo.2021.5167

PubMed: 33491755 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2020, 117(46):29025-29034

PubMed: 33144503 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

EBioMedicine, 2020, 62:103131

PubMed: 33254023 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2697

PubMed: 32967224 ( click the link to review the publication )

Br J Cancer, 2020, 22

PubMed: 32439932 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-0952-1

PubMed: 32572172 ( click the link to review the publication )

Cell Oncol (Dordr), 2020, 10.1007/s13402-020-00562-0

PubMed: 33119860 ( click the link to review the publication )

Front Oncol, 2020, 10;10:331

PubMed: 32211337 ( click the link to review the publication )

Int J Mol Sci, 2020, 18;21(8):2825

PubMed: 32325639 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 10.1038/s41401-020-00567-3

PubMed: 33288861 ( click the link to review the publication )

Oncol Rep, 2020, 44(6):2581-2594

PubMed: 33125153 ( click the link to review the publication )

EMBO Mol Med, 2020, e11793

PubMed: 32720440 ( click the link to review the publication )

Biochem Genet, 2020, 10.1007/s10528-020-09982-x

PubMed: 32671511 ( click the link to review the publication )

BMC Pharmacol Toxicol, 2020, 21(1):61

PubMed: 32795383 ( click the link to review the publication )

Mol Cancer Res, 2020, 18(4):549-559

PubMed: 31941753 ( click the link to review the publication )

Stem Cell Res Ther, 2020, 11(1):67

PubMed: 32070424 ( click the link to review the publication )
Nat Commun, 2019, 10(1):2701

PubMed: 31221965 ( click the link to review the publication )

EMBO Mol Med, 2019, 11(2)

PubMed: 30610113 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2331-2344

PubMed: 31461650 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):372

PubMed: 31438996 ( click the link to review the publication )

Aging (Albany NY), 2019, 11(18):7780-7795

PubMed: 31545294 ( click the link to review the publication )

Mol Cancer Res, 2019,

PubMed: 30257990 ( click the link to review the publication )

J Cell Mol Med, 2019, 23(4):2933-2942

PubMed: 30761743 ( click the link to review the publication )

J Cell Mol Med, 2019, 101111/jcmm14793

PubMed: 31692229 ( click the link to review the publication )

Sci Rep, 2019, 9(1):8726

PubMed: 31217507 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1875

PubMed: 30755670 ( click the link to review the publication )

Sci Rep, 2019, 9(1):6004

PubMed: 30979919 ( click the link to review the publication )

Front Pharmacol, 2019,

PubMed: 31998131 ( click the link to review the publication )

Transl Oncol, 2019, 12(3):432-440

PubMed: 30562682 ( click the link to review the publication )

Reprod Sci, 2019, 26(7):979-987

PubMed: 30270745 ( click the link to review the publication )

Ocul Immunol Inflamm, 2019, 10.1080/09273948.2019.1672196

PubMed: 31657648 ( click the link to review the publication )

Oncol Lett, 2019, 18(6):6249-6260

PubMed: 31788102 ( click the link to review the publication )

Oncol Lett, 2019, 17(2):2303-2307

PubMed: 30719110 ( click the link to review the publication )

Hepatology, 2018, 10.1002/hep.30127

PubMed: 30067876 ( click the link to review the publication )

Cancer Lett, 2018, 427:38-48

PubMed: 29679612 ( click the link to review the publication )

Mol Cell Proteomics, 2018, 17(5):850-870

PubMed: 29371290 ( click the link to review the publication )

Oncogenesis, 2018, 7(9):71

PubMed: 30237393 ( click the link to review the publication )

Sci Rep, 2018, 8(1):12087

PubMed: 30108259 ( click the link to review the publication )

J Proteomics, 2018, 170:130-140

PubMed: 28842319 ( click the link to review the publication )

Oncotarget, 2018, 9(100):37352-37366

PubMed: 30647837 ( click the link to review the publication )
Clin Cancer Res, 2017, 23(4):962-973

PubMed: 27535980 ( click the link to review the publication )

Clin Cancer Res, 2017, 15;23(18):5527-5536

PubMed: 28630215 ( click the link to review the publication )

Theranostics, 2017, 7(4):974-986

PubMed: 28382169 ( click the link to review the publication )

Oncogene, 2017, 10.1038/onc.2016.512

PubMed: 28263980 ( click the link to review the publication )

BMC Cancer, 2017, 17(1):191

PubMed: 28292264 ( click the link to review the publication )

PLoS One, 2017, 12(8):e0183181

PubMed: 28806774 ( click the link to review the publication )

J Med Invest, 2017, 64(3.4):262-265

PubMed: 28954993 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29050315 ( click the link to review the publication )

Oncotarget, 2017, 8(6):10007-10024

PubMed: 28052020 ( click the link to review the publication )

Oncotarget, 2017, 8(70):115596-115608

PubMed: 29383184 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(15):3884-93

PubMed: 26936917 ( click the link to review the publication )

Cancer Res, 2016, 76(11):3285-94

PubMed: 27197170 ( click the link to review the publication )

Int J Cancer, 2016,

PubMed: 26481559 ( click the link to review the publication )

Oncogene, 2016, 10.1038/onc.2016.216

PubMed: 27345413 ( click the link to review the publication )

J Neurosci, 2016, 36(16):4534-48

PubMed: 27098696 ( click the link to review the publication )

J Proteome Res, 2016, 15(12):4490-4504

PubMed: 27794612 ( click the link to review the publication )

Hum Mol Genet, 2016, 25(1):9-23

PubMed: 26494904 ( click the link to review the publication )

Oncotarget, 2016, 7(31-:50161-50179

PubMed: 27367030 ( click the link to review the publication )

Oncotarget, 2016, 7(18-:25983-6002

PubMed: 27036020 ( click the link to review the publication )

Nat Commun, 2015, 6:7002

PubMed: 25926053 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(10):2292-302

PubMed: 26294741 ( click the link to review the publication )

J Biol Chem, 2015, 290(44):26752-64

PubMed: 26370090 ( click the link to review the publication )

Scand J Rheumatol, 2015, 6:1-10

PubMed: 25743336 ( click the link to review the publication )

PLoS One, 2015, 10(6):e0123967

PubMed: 26053020 ( click the link to review the publication )
PLoS One, 2015, 10(4):e0124562

PubMed: 25893435 ( click the link to review the publication )

Pathol Oncol Res, 2015, 10.1007/s12253-015-9916-9

PubMed: 25749811 ( click the link to review the publication )

Tumour Biol, 2015, 10.1007/s13277-015-3237-1

PubMed: 25691251 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25576915 ( click the link to review the publication )

Cell Physiol Biochem, 2014, 33(3):633-45

PubMed: 24642893 ( click the link to review the publication )

Gastric Cancer, 2014, 10.1007/s10120-014-0444-1

PubMed: 25407459 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(18):3535-45

PubMed: 25022753 ( click the link to review the publication )

Celon Pharma Inc, 2013, Paulina Grygielewicz

PubMed: ( click the link to review the publication )

产品安全说明书

FGFR抑制剂选择性比较

生物活性

产品描述

特性

AZD4547高选择性作用于 FGFR1-3，比作用于FGFR4选择性高。AZD4547有效作用于野生型和突变型FGFR酪氨酸激酶活性。

靶点

FGFR1 ^[1] (Cell-free assay)	FGFR3 ^[1] (Cell-free assay)	FGFR2 ^[1] (Cell-free assay)	KDR ^[1] (Cell-free assay)
0.2 nM	1.8 nM	2.5 nM	24 nM

体外研究

与 FGFR1-3相比, AZD4547作用于FGFR4，活性微弱，IC50为165 nM。AZD4547 只抑制重组 VEGFR2 (KDR) 激酶活性， IC50为 24 nM,在体外选择性作用于一组多种代表性的人类激酶。0.1 μM AZD4547 作用于一系列重组激酶，包括 ALK, CHK1, EGFR, MAPK1, MEK1, p70S6K, PDGFR, PKB, Src, Tie2,和 PI3K，没有作用活性。相应地,在细胞磷酸化实验中，可观察到AZD4547 作用于FGFR1-3的选择性比作用于 FGFR4, IGFR, 和 KDR高。AZD4547在体外,只有作用于表达去调控FGFRs 如KG1a, Sum52-PE,和KMS11的肿瘤细胞，具有有效抗增殖活性，IC50 为18-281 nM,而对MCF7 及100 种以上其他肿瘤细胞无活性。AZD4547 处理人类肿瘤细胞，有效抑制FGFR 和 MAPK 磷酸化,这种作用存在剂量依赖性。AZD4547 也有效抑制FRS2 和 PLCγ磷酸化,及下游FGFR信号。另外, AZD4547作用于乳腺细胞系，MCF7和Sum52-PE 而不是KG1a和 KMS11细胞，影响AKT磷酸化。AZD4547处理Sum52-PE 和 KMS11细胞，显著诱导凋亡,作用于KG1a细胞，显著提高细胞周期在G1期停滞而不是凋亡, 而作用于MCF7细胞，对细胞周期分布和凋亡都没有作用效果。^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
SNU449	NVPqSJJsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnHBO\|IhcA>?	MmTFTWM2OD1yLkC4NkDPxE1?	MlXDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|NUGzNlAoRjJ4M{WxN\|IxRC:jPh?=
SK-HEP-1	MnTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWq3NkBp	MYjJR\|UxRTBwMEi0JO69VQ>?	NHjBdpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO1NVMzOCd-Mk[zOVE{OjB:L3G+
SNU475	NXPuXmpsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NEPsTIw4OiCq	NET5PW9KSzVyPUWuOEDPxE1?	Mn3YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|NUGzNlAoRjJ4M{WxN\|IxRC:jPh?=
Hep3B	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NYnuTFQ1PzJiaB?=	NHzMeoVKSzVyPU[uOFMh\|ryP	MoDiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|NUGzNlAoRjJ4M{WxN\|IxRC:jPh?=
PLC/PRF5	MkTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHfVTZY4OiCq	NXfkOIFpUUN3ME22MlU2KM7:TR?=	NEHxdmE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO1NVMzOCd-Mk[zOVE{OjB:L3G+
Hur7	NX3VcZJYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXK3NkBp	NFvic29KSzVyPUeuNlUh\|ryP	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN3MUOyNEc,OjZ\|NUGzNlA9N2F-
HepG2	M2DXZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2fGUFczKGh?	MlLzTWM2OD16LkezJO69VQ>?	MojDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|NUGzNlAoRjJ4M{WxN\|IxRC:jPh?=
SNU449	MmXUR4xwdm:pZX7pZ{Bie3OjeR?=	M2HXPVEhyrWP	MYOyOEBp	NE\ONnZl\WO{ZXHz[ZMh[2:ub375JIZwem2jdHnvckB{cWewaX\pZ4FvfGy7	M164TlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{WxN\|IxLz5{NkO1NVMzODxxYU6=
SK-HEP-1	NGLudVBEdG:wb3flcolkKGG\|c3H5	MXmxJOK2VQ>?	NIDTTHgzPCCq	NUPtd\|Vi\GWlcnXhd4V{KGOxbH;ufUBnd3KvYYTpc44he2mpbnnmbYNidnSueR?=	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN3MUOyNEc,OjZ\|NUGzNlA9N2F-
SNU449	M4TqNGZ2dmO2aX;uJGF{e2G7	NXrqXWJbOC1{IN88US=>	MY[0PEBp	NHL0d2xk[XW\|ZYOgZUBl\WO{ZXHz[UBw\iCIUmOy89yNSUuWLDDhcoQhTVKNIIDoc5NxcG:{eXzheIlwdg>?	NYnJPI9CRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zOVE{OjBpPkK2N\|UyOzJyPD;hQi=>
SK-HEP-1	NVu5flB1TnWwY4Tpc44hSXO\|YYm=	NWiyTGg3OC1{IN88US=>	Mkn5OFghcA>?	MUfjZZV{\XNiYTDk[YNz\WG\|ZTDv[kBHWlN{78{MRWtVNCCjbnSgSXJMKHCqb4PwbI9zgWyjdHnvci=>	NULEfm44RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zOVE{OjBpPkK2N\|UyOzJyPD;hQi=>
BaF3 FLT3-TEL	NIniRlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NWrGVGRuT0l3ME20MlYhyrFiMD61O\|ch\|ryP	Ml[3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{OUS3OFEoRjJ4Mkm0O\|QyRC:jPh?=
BaF3 RET-TEL	NGPBUJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MV\HTVUxRTBwM{mgxtEhOC5yNEig{txO	MnrMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{OUS3OFEoRjJ4Mkm0O\|QyRC:jPh?=
BaF3 Parental	M2LMNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MkL4S2k2OO,7pUGwJO69VQ>?	NFXWeIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK5OFc1OSd-Mk[yPVQ4PDF:L3G+
MOLM14 FLT3/ITD	MnnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NXn2bXNtT0l3ME2wMlQ5PCEEsTCwMlE2PyEQvF2=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ7NEe0NUc,OjZ{OUS3OFE9N2F-
MV4-11 FLT3/ITD	M2jpeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NWfOfVZDT0l3ME2wMlQ2QSEEsTCwMlA1PiEQvF2=	M2q1cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4Mkm0O\|QyLz5{NkK5OFc1OTxxYU6=
TT RET C634W	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MV;HTVUxRTJwOTFCtUAxNjlyNDFOwG0>	NFftNlg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK5OFc1OSd-Mk[yPVQ4PDF:L3G+
AN3-CA FGFR2 N550K, K310R	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MXXHTVUxRTBwMEOxJOKyKDBwMEKzJO69VQ>?	NXj2ZWpGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yPVQ4PDFpPkK2Nlk1PzRzPD;hQi=>
MFE296 FGFR2 N550K	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MkLaS2k2OD1yLkezNEDDuSByLkC1O{DPxE1?	NWnNc2VPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yPVQ4PDFpPkK2Nlk1PzRzPD;hQi=>
MFE280 FGFR2 S252W	MkXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MYXHTVUxRTBwMkG4JOKyKDBwMEezJO69VQ>?	NXvXO3FDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yPVQ4PDFpPkK2Nlk1PzRzPD;hQi=>
Ishikawa FGFF2 over exp.	NH;JU5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NWXIR4VmT0l3ME20MlUhyrFiMT61NUDPxE1?	Mn;rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{OUS3OFEoRjJ4Mkm0O\|QyRC:jPh?=
HEC1A Normal FGFR2	NGPhbmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NYfWSZJXT0l3MP-5qVExKM7:TR?=	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ7NEe0NUc,OjZ{OUS3OFE9N2F-
A549	NFPrZopE\WyuII\pZYJqdGm2eTDBd5NigQ>?	M3TwVlAvOS9zIN88US=>	NFuxS4E1QCCq	NHLR[WhmdmijbnPld{BGemyxdHnubYIhcW6mdXPl[EB3cWGkaXzpeJkhdG:\|cx?=	MmPsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNUOwNlAoRjJ4MEWzNFIxRC:jPh?=
SGC-7901	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXLyWYhiOSCwTT2xNEDPxE1?	MX:3NkBp	NV3JT2tLUUN3MDDv[kA2NTFyIN88UUwhcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?=	M4DyT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUe2PVE2Lz5{NUW3OlkyPTxxYU6=
HGC-27	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYqxJI5ONTFyIN88US=>	Ml3hO\|IhcA>?	MmO0TWM2OCCxZjC1MVExKM7:TTygbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>?	NVj0XpRRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1O\|Y6OTVpPkK1OVc3QTF3PD;hQi=>
MKN-28	Mn;uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX[2cYxLOSCwTT2xNEDPxE1?	MVi3NkBp	NUPrVHYzUUN3MDDv[kA2NTFyIN88UUwhcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?=	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV5NkmxOUc,OjV3N{[5NVU9N2F-
NCI-N87	M1jVSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3vuUlEhdk1vMUCg{txO	MV23NkBp	MX\JR\|UxKG:oIEWtNVAh\|ryPLDDpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6	Ml33QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3N{[5NVUoRjJ3NUe2PVE2RC:jPh?=
KATOIII	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{f5elEhdk1vMUCg{txO	M2HneVczKGh?	M{LZeGlEPTBib3[gNVAuOTByIH7NMEBqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV5NkmxOUc,OjV3N{[5NVU9N2F-
SNU-16	NGTTU5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{fnOFEhdk1vMUCg{txO	NWHaOm9QPzJiaB?=	M1vJXGlEPTBib3[gNVAuOTByIH7NMEBqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7	NGP2Om09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW3OlkyPSd-MkW1O\|Y6OTV:L3G+
4T1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MnvGTWM2OD1yLk[0xtExNjFzIN88US=>	M1XLbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkSyPFk{Lz5{NE[0Nlg6OzxxYU6=
MDA-MB-468	NIX5d4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NWjGTFVtUUN3ME20MlnDuTBwOEWg{txO	NEm1NWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[0Nlg6Oyd-MkS2OFI5QTN:L3G+
HCT116	NIjONZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MV7JR\|UxRTF3LkpCtVEvQDJizszN	NWjCNY1nRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2OFI5QTNpPkK0OlQzQDl\|PD;hQi=>
SW620	NVL2VJZuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NWPKRZVbUUN3MP-8olIxKM7:TR?=	NELtSXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[0Nlg6Oyd-MkS2OFI5QTN:L3G+
MDA-MB-231	Mk\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M{LYTWlEPTExvK6yNEDPxE1?	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ2Mki5N{c,OjR4NEK4PVM9N2F-
CT26	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MVzJR\|Ux97zgMkCg{txO	Mn7QQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4NEK4PVMoRjJ2NkSyPFk{RC:jPh?=
SW480	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NVX5NVdUUUN3MP-8olIxKM7:TR?=	MlX6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4NEK4PVMoRjJ2NkSyPFk{RC:jPh?=
4T1	M2f6XmFxd3C2b4Ppd{BCe3OjeR?=	NUj0cmV1OS5{NT2yNEDPxE1?	NIT1c4gzPCCq	M2DBcolv\HWlZYOgZZBweHSxc3nzJIRwe2ViZHXw[Y5l\W62bIm=	MkO0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4NEK4PVMoRjJ2NkSyPFk{RC:jPh?=
KG1a	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MVTJR\|UxRTBwMEG4JO69VQ>?	NGTv[ZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkO2PVkzQCd-MkKzOlk6Ojh:L3G+
Sum52-PE	NWTifmhHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NXLoU\|ZuUUN3ME2wMlA1OSEQvF2=	NGTCVXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkO2PVkzQCd-MkKzOlk6Ojh:L3G+
KMS11	NXW5[VJJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NGfG[IFKSzVyPUCuNlgyKM7:TR?=	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN4OUmyPEc,OjJ\|Nkm5Nlg9N2F-
MCF7	MmHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NITmVHhKSzVyPkOwJO69VQ>?	NGXUZ3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkO2PVkzQCd-MkKzOlk6Ojh:L3G+
KG1	NGDNWoZHfW6ldHnvckBie3OjeR?=		M1\wblczKGi{cx?=	M{fNVmlvcGmkaYTpc44hd2ZiRlfGVlEhcW5iaIXtZY4hU0dzIHPlcIx{KGG\|c3Xzd4VlKGG\|IIP1dJBz\XO\|aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiCjZoTldkA4OiCqcoOgZpkhW1KEL1PDT{05KGG\|c3H5MEBKSzVyIE2gNE4xODB{IN88UU4>	NG\zRWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GxO\|QzPyd-MkexNVc1Ojd:L3G+
RT112	NVnFVY9rTnWwY4Tpc44h[XO\|YYm=		MYS3NkBpenN?	NHzlW5lKdmirYnn0bY9vKG:oIF\HSnI{KGmwIHj1cYFvKFKWMUGyJINmdGy\|IHHzd4V{e2WmIHHzJJN2eHC{ZYPzbY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbjDh[pRmeiB5MjDodpMh[nliU2LCM2NEUy16IHHzd4F6NCCLQ{WwJF0hOC5yMEC2JO69VS5?	M3ftUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUG3OFI4Lz5{N{GxO\|QzPzxxYU6=
KG1	M1rUOmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MkXtO\|IhcHK\|	MnvDRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCNR{GgZ4VtdHNiZYjwdoV{e2mwZzDGS2ZTOSCjZoTldkA4OiCqcoOsJGlEPTBiPTCwMlAxOTlizszNMi=>	NGfidWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUe3OVk{Pyd-Mkm3O\|U6Ozd:L3G+
KG1	Mo\0RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MnPUO\|IhcHK\|	NHjiTG5CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFvHNUBk\WyuczDh[pRmeiB5MjDodpMh[nliQ1PLMVgh[XO\|YYmsJGlEPTBiPTCwMlAxOzNizszNMi=>	NFXOcpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OE[4O\|IxPCd-Mki2PFczODR:L3G+
SNU16	M2PHRmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MYW3NkBpenN?	MnmxRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCVTmWxOkBk\WyuczDh[pRmeiB5MjDodpMh[nliQ1PLMVgh[XO\|YYmsJGlEPTBiPTCwMlAxOzRizszNMi=>	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDZ6N{KwOEc,Ojh4OEeyNFQ9N2F-
SNU16	Ml3WSpVv[3Srb36gZZN{[Xl?		NETqV2w4OiCqcoO=	NGK2bnNKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JGZITlJ{IHnuJIh2dWGwIGPOWVE3KGOnbHzzJIF{e2W\|c3XkJIF{KHO3cIDy[ZN{cW:wIH;mJINmdGxicILvcIln\XKjdHnvckBi\nSncjC3NkBpenNiYomgV3JDN0OFSz24JIF{e2G7LDDJR\|UxKD1iMD6wNFM3KM7:TT6=	NYLEZ3NvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexNVc1OjdpPkK3NVE4PDJ5PD;hQi=>
SNU16	NELod2lCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NY\XdZJoPzJiaILz	M13mXmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU17VNVYh[2WubIOg[ZhxemW\|c3nu[{BHT0[UMjDh[pRmeiB5MjDodpMtKEmFNUCgQUAxNjByNkKg{txONg>?	NFq2N\|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUe3OVk{Pyd-Mkm3O\|U6Ozd:L3G+
KG1	M2qzdmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NXX1VJNLPzJiaILz	MVvBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IF\HSnIyNXS{YX7zcI9k[XSnZDDoeY1idiCNR{GgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOFS{ivUXRVKGG\|c3H5MEBKSzVyIE2gNE4xODZ2IN88UU4>	NF;xXYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{O0PFU{Pyd-MkezOFg2Ozd:L3G+
SNU16	NXTjS4ZrSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MYO3NkBpenN?	MXzBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IF\HSnIzNWGvcHzp[olm\CCqdX3hckBUVlVzNjDj[YxteyCjZoTldkA4OiCqcoOgZpkhS0ONOD;NWHQh[XO\|YYmsJGlEPTBiPTCwMlAyOzRizszNMi=>	Ml7CQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd\|NEi1N\|coRjJ5M{S4OVM4RC:jPh?=
KATO III	NULKTZpxTnWwY4Tpc44h[XO\|YYm=		MVS3NkBpenN?	M3LwUmlvcGmkaYTpc44hd2ZiRlfGVlIhcW5iaIXtZY4hU0GWTzDJTWkh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IHPlcIwh[2:3boTpcochc2m2LUigZZN{[XluIFnDOVAhRSByLkCxOFEh\|ryPLh?=	NYDkUnBxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3NVQ3QTJpPkK4O\|E1Pjl{PD;hQi=>
KG1	M{\LSmZ2dmO2aX;uJIF{e2G7		NXvBcWtmPzJiaILz	NXvIbIw2UW6qaXLpeIlwdiCxZjDGS2ZTOU:SMjDmeZNm\CCIR1\SNUBqdiCqdX3hckBMTzFiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[W[2ZYKgO\|IhcHK\|IHL5JINmdGxiY3;1cpRqdmdia3n0MVgh[XO\|YYmsJGlEPTBiPTCwMlAyPjFizszNMi=>	NWDNOWlrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3NVQ3QTJpPkK4O\|E1Pjl{PD;hQi=>
KATO III	MkPoSpVv[3Srb36gZZN{[Xl?		NWTx[5ZIPzJiaILz	MYTJcohq[mm2aX;uJI9nKE[JRmKyJIlvKGi3bXHuJGtCXE9iSVnJJINmdGy\|IHHzd4V{e2WmIHHzJJN2eHC{ZYPzbY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbjDh[pRmeiB5MjDodpMh[nliU2LCM2NEUy16IHHzd4F6NCCLQ{WwJF0hOC5yMkCyJO69VS5?	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzFzN{SyO{c,OjdzMUe0Nlc9N2F-
SNU16	NW\4ZXFtTnWwY4Tpc44h[XO\|YYm=		M3WxbVczKGi{cx?=	MljZTY5pcWKrdHnvckBw\iCIR1\SNkBqdiCqdX3hckBUVlVzNjDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiCjZoTldkA4OiCqcoOgZpkh[2WubDDjc5VvfGmwZzDrbZQuQCCjc4PhfUwhUUN3MDC9JFAvODJ3NDFOwG0v	M{LRSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{G0OlkzLz5{OEexOFY6OjxxYU6=
UM-UC-14	NYTlZ297SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NUnHPYQ5PzJiaILz	MY\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFWPLWXDMVE1KGOnbHzzJIV5eHKnc4PpcochTkeIUkOgZYZ1\XJiN{KgbJJ{NCCLQ{WwJF0hOC5yMk[5JO69VS5?	M1z1b\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{e1PVM4Lz5{OUe3OVk{PzxxYU6=
RT112	MnHDSpVv[3Srb36gZZN{[Xl?		NWHReWdoPzJiaILz	M3mzTGlvcGmkaYTpc44hd2ZiRlfGVlMhcW5iaIXtZY4hWlRzMUKgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25iYX\0[ZIhPzJiaILzJIJ6KGOnbHygZ492dnSrbnegb4l1NThiYYPzZZktKEmFNUCgQUAxNjB{NzFOwG0v	NFTJeno9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEexOFY6Oid-Mki3NVQ3QTJ:L3G+
UM-UC-14	NYDmdFF{TnWwY4Tpc44h[XO\|YYm=		M1r0dFczKGi{cx?=	NFi2XFBKdmirYnn0bY9vKG:oIF\HSnI{KG23dHHueEBqdiCqdX3hckBWVS2XQz2xOEBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbjDh[pRmeiB5MjDodpMh[nliY3XscEBkd3WwdHnu[{BscXRvODDhd5NigSxiSVO1NEA:KDBwMEK3NUDPxE1w	M1XQflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{G0OlkzLz5{OEexOFY6OjxxYU6=
RT112	M4LQfmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MVK3NkBpenN?	MYPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFKWMUGyJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFfJOVAhRSByLkCyPVIh\|ryPLh?=	NXrEVGZzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke1PVk4PDJpPkK3OVk6PzR{PD;hQi=>
H1581	NFv0d3BHfW6ldHnvckBie3OjeR?=		NGrZb5Q4OiCqcoO=	MnH2TY5pcWKrdHnvckBw\iCIR1\SNUBqdiCqdX3hckBJOTV6MTDj[YxteyCjc4Pld5Nm\CCjczDzeZBxemW\|c3nvckBw\iClZXzsJJBzd2yrZnXyZZRqd25iYX\0[ZIhPzJiaILzJIJ6KFOUQj;DR2suQCCjc4PhfUwhUUN3MDC9JFAvODN{OTFOwG0v	MlrZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzMUe0NlcoRjJ5MUG3OFI4RC:jPh?=
NCI-H1581	MXHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MWC3NkBpenN?	NGrnXmZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JOTV6MTDj[YxteyCneIDy[ZN{cW6pIF\HSnIyKGGodHXyJFczKGi{czygTWM2OCB;IECuNFQh\|ryPLh?=	MlPzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5N{W5N\|coRjJ7N{e1PVM4RC:jPh?=
B16F10	MmTER5l1d3SxeHnjbZR6KGG\|c3H5		NYDjNoVsPzJiaILz	MWjDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCNVZHOTBiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvODVzIN88UU4>	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd\|Nkm5N{c,OjV5M{[5PVM9N2F-
A549	M4HxWWN6fG:2b4jpZ4l1gSCjc4PhfS=>		NUDmN2F2PzJiaILz	MnfSR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNE4xPjJizszNMi=>	Moq5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5M{[5PVMoRjJ3N{O2PVk{RC:jPh?=
NCI-H1581	NV61XZhVTnWwY4Tpc44h[XO\|YYm=		MVK3NkBpenN?	NIn6foZKdmirYnn0bY9vKG:oIF\HSnIyKGmwIHj1cYFvKE6FST3INVU5OSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJINmdGxicILvcIln\XKjdHnvckBi\nSncjC3NkBpenNiYomgZ4VtdCClb4XueIlv\yCtaYStPEBie3OjeTygTWM2OCB;IECuNFYzPiEQvF2u	MnH1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh5MUS2PVIoRjJ6N{G0OlkzRC:jPh?=
RT112	NEPLbmRCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MUS3NkBpenN?	NF:1cWlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGLUNVEzKGOnbHzzJIV5eHKnc4PpcochTkeIUkOgZYZ1\XJiN{KgbJJ{NCCLQ{WwJF0hOC5yOEO4JO69VS5?	NIHBNJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUe3OVk{Pyd-Mkm3O\|U6Ozd:L3G+
RT112	MWfBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NVf1[GlVPzJiaILz	M1S4NmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgSmdHWjNvYX3wcIlncWWmIHj1cYFvKFKWMUGyJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCFQ1u4M21VXCCjc4PhfUwhUUN3MDC9JFAvODh6NDFOwG0v	M4fzV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5M{S4OVM4Lz5{N{O0PFU{PzxxYU6=
NCI-H1581	NI\nc5RCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MVm3NkBpenN?	NIDxS29CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGZITlJzLXHtdIxq\mmnZDDoeY1idiCQQ1mtTFE2QDFiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JGNEUzhxTWTUJIF{e2G7LDDJR\|UxKD1iMD6wPVIyKM7:TT6=	NF7RcYU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{O0PFU{Pyd-MkezOFg2Ozd:L3G+
HeLa 229	NYLh[ZJOS3m2b4TvfIlkcXS7IHHzd4F6		Mn70O\|IhcHK\|	MUfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[WxiKDJ{OTDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC5zNDFOwG0v	MnPmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5M{[5PVMoRjJ3N{O2PVk{RC:jPh?=
BAF3	MUPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NXvydZE3PzJiaILz	Mn7qRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCEQV[zJINmdGy\|IHX4dJJme3OrbnegWmVITlJ{IHHmeIVzKDd{IHjyd{whUUN3MDC9JFAvOjJ{IN88UU4>	NUW5XnAyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3O\|U6OzdpPkK5O\|c2QTN5PD;hQi=>
SGC7901	NYT3ZpRqSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MmDXO\|IhcHK\|	NWDSSYhpSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTS2M4QTBzIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAzNjhizszNMi=>	NGrrXlg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{iyPVUyQSd-Mke4Nlk2OTl:L3G+
MGC803	M4fQVGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MofuO\|IhcHK\|	NYnpbYdiSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNS2M5ODNiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFYvOiEQvF2u	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzh{OUWxPUc,Ojd6Mkm1NVk9N2F-
BGC823	MXXBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MV[3NkBpenN?	M17wbGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQlfDPFI{KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTC3Mlkh\|ryPLh?=	NVfZNWxRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke4Nlk2OTlpPkK3PFI6PTF7PD;hQi=>
HL7702	NVy1V4oyS3m2b4TvfIlkcXS7IHHzd4F6		NIG3Zog4OiCqcoO=	M2X1SWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhNPzdyMjDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOThwMkGg{txONg>?	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd\|Nkm5N{c,OjV5M{[5PVM9N2F-
U-2 OS	NX7IfItueUiWUzDzd4F6			MVrxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhXS1{IF;TJINmdGy\|	MlfSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
A673	NVzCbJlyeUiWUzDzd4F6			MW\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>?	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Saos-2	NUXjUJJjeUiWUzDzd4F6			NEDMcZFyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU3Hvd{0zKGOnbHzz	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
BT-37	NFrPPVhyUFSVIIPzZZk>			MoT6dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUO3JINmdGy\|	M3TDcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD	MWLxTHRUKHO\|YYm=			M3vYcJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCURDDj[Yxtew>?	NHnZfHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-SH	NVnxZpN3eUiWUzDzd4F6			MUnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3TTEBk\Wyucx?=	NXT3NXZKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-12	M1jRbJFJXFNic4PhfS=>			MXzxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvMUKgZ4VtdHN?	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
OHS-50	MofCdWhVWyC\|c3H5			Mn7OdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?=	Ml3GQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
fibroblast cells	M3L3WpFJXFNic4PhfS=>			MXnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5Ih[2:wdILvcEBJcCC5aXzkJJR6eGViZnnido9jdGG\|dDDj[Yxtew>?	NF\yPWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh41	NEDxSotyUFSVIIPzZZk>			MYPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmh2MTDj[Yxtew>?	NXzqWnllRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh30	MXrxTHRUKHO\|YYm=			M1X1ZpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaEOwJINmdGy\|	M3HxOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SJ-GBM2	M2rQdJFJXFNic4PhfS=>			NETJRW9yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1qtS2JOOiClZXzsdy=>	NWnINpA2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1	MkD4dWhVWyC\|c3H5			MUPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJvRVLjNUBk\Wyucx?=	MlzIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
LAN-5	M3;WVJFJXFNic4PhfS=>			NX7UbnJneUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFzBUk02KGOnbHzz	Ml\oQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh18	M{nHb5FJXFNic4PhfS=>			M3jjcpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaEG4JINmdGy\|	M{TSfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-FGFR / FGFR1 / p-AKT / AKT / p-ERK / ERK; PubMed: 28900173 Sci Rep Western blots (cropped) are shown for the indicated proteins in MDA-MB-361, BT474, and SKBR3 cells treated with AZD4547 (0, 1, 3, or 5 µM) for 72 hours. pFRS2; PubMed: 25576915 Oncotarget AZD4547 inhibits FGFR2 pathway activation in SNU16 and KATOIII cells. Cells were incubated with AZD4547 at the indicated doses. Cell lysates were immunoblotted for phospho-FGFR, phospho-FRS2, phospho- and total AKT, and phospho- and total ERK.	28900173 25576915
Growth inhibition assay	Cell viability; PubMed: 28900173 Sci Rep MDA-MB-361, BT474, and SKBR3 ErbB2-overexpressing breast cancer cells were treated with AZD4547 (0, 0.1, 0.3, 1, 3, or 5 µM) for 5 days. Then the viable fraction of each cell line was determined with an MTS assay. Cell viability; PubMed: 25576915 Oncotarget FGFR2-amplified GC cells are selectively sensitive to AZD4547. In vitro CCK-8 assay across a panel of 6 GC cells demonstrated that SNU16 and KATOIII cells were extremely sensitive to AZD4547 with IC50 values of 5-10 nM. Data (n = 6) are presented as mean ± SD.	28900173 25576915

体内研究

AZD4547按3 mg/kg剂量口服处理携带KMS11肿瘤的小鼠，每天两次，与空白对照组相比，显著抑制53%肿瘤生长，AZD4547 按 12.5 mg/kg剂量每天处理一次，或按 6.25 mg/kg剂量每天处理两次，则完全抑制肿瘤，这与p-FGFR3的药效学调节剂量正相关，且降低 KMS11肿瘤细胞增殖。而且, AZD4547按 12.5 mg/kg剂量口服处理给药FGFR1融合KG1a 移植瘤模型，每天一次，抑制65% 肿瘤生长。在有效剂量水平，AZD4547不表现出抗血管生成的效果。AZD4547 对血压没有显著作用效果，因此在体内缺乏抗-KDR 活性。相应地, AZD4547按6.25 mg/kg剂量口服处理对Cediranib敏感的移植瘤模型，包括 Calu-6, HCT-15 和 LoVo，每天两次，没有作用活性。^[1]

激酶实验：^[1]	- 合并 AZD4547 激酶活性: 使用浓度等于或低于相对K_m 的ATP，测定AZD4547抑制 FGFR1-3的人类重组激酶活性的效果。
细胞实验：^[1]	- 合并 Cell lines: KG1a, Sum52-PE, KMS11, 和MCF7 Concentrations: 溶于DMSO,终浓度为 ~1 μM Incubation Time: 72 小时 Method: 使用多种浓度AZD4547处理细胞72小时。通过 MTS 增殖实验获得抗增殖的IC50值。荧光激活细胞分选(FACS)中,细胞与70%乙醇混合，然后与碘化丙啶/RNase A标记溶液温育。使用 FACSCalibur 仪器和CellQuest分析软件测定细胞周期谱。为了分析凋亡，轻轻收集细胞和培养基，离心，然后冲洗细胞颗粒。细胞进行Annexin膜联蛋白 V-异硫氰酸荧光素(FITC)染色和碘化丙啶吸收。使用FACSCalibur仪器测定膜联蛋白 V染色阳性细胞比例，使用CellQuest分析软件进行象限分类。 (Only for Reference)
动物实验：^[1]	- 合并 Animal Models: 皮下注射LoVo, HCT-15, Calu-6, KMS11 或 KG1a的雌性Swiss衍生裸鼠和SCID小鼠 Dosages: 1.5-50 mg/kg Administration: 口服饲喂，每天一次或两次 (Only for Reference)

参考文献

[1] Gavine PR, et al. Cancer Res, 2012, 72(8), 2045-2056.

溶解度 (25°C)

体外	DMSO	92 mg/mL (198.45 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 4% DMSO+30% PEG 300+5% Tween 80+ddH2O	5mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download AZD4547 SDF

分子量	463.57
化学式	C₂₆H₃₃N₅O₃
CAS号	1035270-39-3
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	ABSK 091

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02824133	Completed	Drug: AZD4547	Recurrent IDHwt Gliomas With FGFR3-TACC3 Fusion\|Recurrent IDHwt Gliomas With FGFR1-TACC1 Fusion	Assistance Publique - Hôpitaux de Paris	September 2015	Phase 1\|Phase 2
NCT01824901	Completed	Drug: docetaxel\|Drug: AZD4547	Recurrent Non-small Cell Lung Cancer\|Squamous Cell Lung Cancer	ECOG-ACRIN Cancer Research Group\|National Cancer Institute (NCI)\|Eastern Cooperative Oncology Group	September 2013	Phase 1\|Phase 2
NCT01795768	Unknown status	Drug: AZD 4547	Gastric Cancer\|Oesophageal Cancer\|Breast Cancer\|Squamous Cell Carcinoma of the Lung	Royal Marsden NHS Foundation Trust\|AstraZeneca	September 2012	Phase 2
NCT01791985	Completed	Drug: AZD4547 / anastrozole or letrozole	Breast Cancer	Imperial College London\|Cancer Research UK\|AstraZeneca	July 2012	Phase 1\|Phase 2
NCT01213160	Completed	Drug: AZD4547	Cancer\|Advanced Solid Malignancies	AstraZeneca	November 2010	Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

FGFR Signaling Pathway Map

FGFR Inhibitors with Unique Features

选择性强的FGFR抑制剂

PD173074 : FGFR1-selective, IC50=~25 nM.
FDA批准的FGFR抑制剂

Ponatinib (AP24534) : Approved by FDA for resistant or intolerant CML and Ph+ ALL.
最新的FGFR抑制剂

SSR128129E ^New : Orally-active and allosteric FGFR1 inhibitor with IC50 of 1.9 μM, while not affecting other related RTKs.
经典的FGFR抑制剂

Dovitinib (TKI-258, CHIR-258) : Multitargeted RTK inhibitor for class III (FLT3/c-Kit), class IV (FGFR1/3) and class V (VEGFR1-4) RTKs.

研究领域

产品类型

定制您的化合物库

AZD4547

客户使用Selleck生产的AZD4547发表文献80篇：

产品安全说明书

FGFR抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download AZD4547 SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-01-06)

技术支持

FGFR Signaling Pathway Map

FGFR Inhibitors with Unique Features

相关FGFR产品